바이러스 벡터 백신 시장 : 질환별, 유형별, 최종사용자별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율, 예측(2025-2032년)

REPORT HIGHLIGHT

Viral vector vaccines market size was valued at US$ 850.43 Million in 2024, expanding at a CAGR of 15.93% from 2025 to 2032.

Viral vector vaccines use a harmless virus as a delivery system to introduce genetic material from a pathogen into the body. This genetic code instructs cells to produce a protein that triggers an immune response without causing disease. These vaccines mimic natural infection, training the immune system to recognize and fight the real virus if exposed later. They are widely used in preventing infectious diseases like COVID-19 and Ebola.

Viral Vector Vaccines Market- Market Dynamics

Increasing prevalence of infectious diseases to propel market demand

The rising incidence of infectious diseases such as COVID-19, influenza, and hepatitis is propelling the demand for effective vaccines. According to the World Health Organization (WHO), vaccines prevent 2 to 3 million deaths annually, highlighting their critical role in global health. In addition, continuous progress in genetic engineering has facilitated the development of more efficient viral vector vaccines. However, instances of adverse effects, although rare, have been reported, leading to public hesitance, which is predicted to hamper the market growth in the coming years. On the contrary, developing regions present significant growth opportunities due to improving healthcare infrastructure and rising awareness about vaccination.

Viral Vector Vaccines Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 15.93% over the forecast period (2025-2032)

Based on Disease segmentation, infectious diseases was predicted to show maximum market share in the year 2024

Based on Type segmentation, adenovirus was the leading Type in 2024

On the basis of region, North America was the leading revenue generator in 2024

Viral Vector Vaccines Market- Segmentation Analysis:

The Global Viral Vector Vaccines Market is segmented on the basis of Disease, Type, End User, and Region.

The market is divided into four categories based on Disease: infectious diseases, cancer, genetic disorders, and others. The infectious diseases segment is expected to hold the major market share in the global viral vector vaccines market during the forecast period. This dominance is primarily driven by the high global burden of infectious diseases and the proven effectiveness of viral vector platforms in developing vaccines against them.

The market is divided into five categories based on Type: adeno-associated virus (AAV), adenovirus, lentivirus, retrovirus, and others. The adenovirus segment is expected to account for the largest market share during the forecast period. This is mainly because adenoviruses are widely used due to their strong immunogenicity, ability to carry large genetic payloads, and suitability for rapid vaccine development.

Viral Vector Vaccines Market- Geographical Insights

The North America region holds the largest share of the global viral vector vaccines market. This dominance is attributed to its advanced healthcare infrastructure, substantial investments in research and development, and the presence of leading pharmaceutical and biotechnology companies. Besides, the Asia-Pacific region is projected to experience the fastest growth in the global market, driven by the increasing healthcare investments, a rising prevalence of infectious diseases, and growing awareness of advanced therapeutic options.

Viral Vector Vaccines Market- Competitive Landscape:

Rising global demand for effective and rapid-response vaccines is driving technological innovation and strategic investment. Companies are focusing on enhancing vector design, improving safety profiles, and expanding manufacturing capabilities to meet surging demand. Partnerships with research institutions and government bodies are common to accelerate development and regulatory approval. Additionally, players are diversifying product pipelines to include vaccines for emerging infectious diseases. Regional expansions and acquisitions are also being pursued to strengthen global presence and increase access to advanced vaccine platforms.

Recent Developments:

In June 2025, ImmunoPrecise Antibodies Ltd. identified a stable epitope common to all four dengue virus serotypes using its AI-powered LENSai(TM) platform. This breakthrough supports progress toward a universal dengue vaccine using epitope-based targeting.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL VIRAL VECTOR VACCINES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

• Advanced Bioscience Laboratories
• Sanofi S.A.
• C.H. Boehringer Sohn AG & Ko
• Brammer Bio, LLC
• GE Healthcare
• Creative Biogene
• Pfizer Inc.
• Moderna Inc.
• Sinovac Biotech Ltd.
• CSL Ltd.
• Astra Zeneca plc
• GSK plc
• Serum Institute of India Pvt. Ltd.
• Merck & Co. Inc.
• Novasep
• Charles River Laboratories
• Waisman Biomanufacturing
• uniQure N.V.
• Creative-Biogene
• Addgene
• Aldevron
• Thermo Fisher Scientific Inc.
• Spark Therapeutics Inc.
• Others

GLOBAL VIRAL VECTOR VACCINES MARKET, BY DISEASE- MARKET ANALYSIS, 2019 - 2032

• Infectious Diseases
• Cancer
• Genetic Disorders
• Others

GLOBAL VIRAL VECTOR VACCINES MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

• Adeno-associated virus (AAV)
• Adenovirus
• Lentivirus
• Retrovirus
• Others

GLOBAL VIRAL VECTOR VACCINES MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

GLOBAL VIRAL VECTOR VACCINES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• The Netherlands
• Sweden
• Russia
• Poland
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Indonesia
• Thailand
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Viral Vector Vaccines Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Viral Vector Vaccines Market Snippet by Disease
  • 2.1.2. Viral Vector Vaccines Market Snippet by Type
  • 2.1.3. Viral Vector Vaccines Market Snippet by End User
  • 2.1.4. Viral Vector Vaccines Market Snippet by Country
  • 2.1.5. Viral Vector Vaccines Market Snippet by Region
• 2.2. Competitive Insights

3. Viral Vector Vaccines Key Market Trends

• 3.1. Viral Vector Vaccines Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Viral Vector Vaccines Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Viral Vector Vaccines Market Opportunities
• 3.4. Viral Vector Vaccines Market Future Trends

4. Viral Vector Vaccines Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Viral Vector Vaccines Market: Impact of Escalating Geopolitical Tensions

• 5.1. Impact of COVID-19 Pandemic
• 5.2. Impact of Russia-Ukraine War
• 5.3. Impact of Middle East Conflicts

6. Viral Vector Vaccines Market Landscape

• 6.1. Viral Vector Vaccines Market Share Analysis, 2024
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Viral Vector Vaccines Market - By Disease

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Disease, 2024 & 2032 (%)
  • 7.1.2. Infectious Diseases
  • 7.1.3. Cancer
  • 7.1.4. Genetic Disorders
  • 7.1.5. Others

8. Viral Vector Vaccines Market - By Type

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
  • 8.1.2. Adeno-associated virus (AAV)
  • 8.1.3. Adenovirus
  • 8.1.4. Lentivirus
  • 8.1.5. Retrovirus
  • 8.1.6. Others

9. Viral Vector Vaccines Market - By End User

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
  • 9.1.2. Pharmaceutical and Biopharmaceutical Companies
  • 9.1.3. Research Institutes

10. Viral Vector Vaccines Market- By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Viral Vector Vaccines Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Viral Vector Vaccines Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.8. UK
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.8.3. UK Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.8.4. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.8.5. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.9. France
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.9.3. France Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.9.4. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.9.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.10. Italy
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.10.3. Italy Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.10.4. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.10.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.11. Spain
    • 10.3.11.1. Overview
    • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.11.3. Spain Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.11.4. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.11.5. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.12. The Netherlands
    • 10.3.12.1. Overview
    • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.12.3. The Netherlands Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.12.4. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.12.5. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.13. Sweden
    • 10.3.13.1. Overview
    • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.13.3. Sweden Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.13.4. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.13.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.14. Russia
    • 10.3.14.1. Overview
    • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.14.3. Russia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.14.4. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.14.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.15. Poland
    • 10.3.15.1. Overview
    • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.15.3. Poland Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.15.4. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3.16. Rest of Europe
    • 10.3.16.1. Overview
    • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Viral Vector Vaccines Key Manufacturers in Asia Pacific
  • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.4.4. APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 10.4.5. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 10.4.6. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.7. China
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.7.3. China Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.7.4. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.7.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.8. India
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.8.3. India Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.8.4. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.8.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.9. Japan
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.9.3. Japan Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.9.4. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.10. South Korea
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.10.3. South Korea Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.10.4. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.12. Indonesia
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.12.3. Indonesia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.12.4. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.12.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.13. Thailand
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.13.3. Thailand Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.13.4. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.13.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4.15. Rest of APAC
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.15.3. Rest of APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.15.4. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 10.5. Latin America (LATAM)
  • 10.5.1. Overview
  • 10.5.2. Viral Vector Vaccines Key Manufacturers in Latin America
  • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.5.4. LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 10.5.5. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 10.5.6. LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
• 10.6. Middle East and Africa (MEA)
  • 10.6.1. Overview
  • 10.6.2. Viral Vector Vaccines Key Manufacturers in Middle East and Africa
  • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.6.4. MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 10.6.5. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  • 10.6.6. MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6.8. UAE
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.8.3. UAE Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.8.4. UAE Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.8.5. UAE Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6.13. Rest of MEA
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.13.3. Rest of MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.13.4. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Viral Vector Vaccines Industry

• 11.1. Competitive Dashboard
  • 11.1.1. Competitive Benchmarking
  • 11.1.2. Competitive Positioning
• 11.2. Company Profiles
  • 11.2.1. Advanced Bioscience Laboratories
  • 11.2.2. Sanofi S.A.
  • 11.2.3. C.H. Boehringer Sohn AG & Ko
  • 11.2.4. Brammer Bio, LLC
  • 11.2.5. GE Healthcare
  • 11.2.6. Creative Biogene
  • 11.2.7. Pfizer Inc.
  • 11.2.8. Moderna Inc.
  • 11.2.9. Sinovac Biotech Ltd.
  • 11.2.10. CSL Ltd.
  • 11.2.11. Astra Zeneca plc
  • 11.2.12. GSK plc
  • 11.2.13. Serum Institute of India Pvt. Ltd.
  • 11.2.14. Merck & Co. Inc.
  • 11.2.15. Novasep
  • 11.2.16. Charles River Laboratories
  • 11.2.17. Waisman Biomanufacturing
  • 11.2.18. uniQure N.V.
  • 11.2.19. Creative-Biogene
  • 11.2.20. Addgene
  • 11.2.21. Aldevron
  • 11.2.22. Thermo Fisher Scientific Inc.
  • 11.2.23. Spark Therapeutics Inc.
  • 11.2.24. Others

12. 360 Degree AnalystView

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us